<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831129</url>
  </required_header>
  <id_info>
    <org_study_id>14863B (SIROCO)</org_study_id>
    <nct_id>NCT00831129</nct_id>
  </id_info>
  <brief_title>A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs</brief_title>
  <acronym>SIROCO</acronym>
  <official_title>Effects of Simvastatin and Rosiglitazone Combination in Patients With the Metabolic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to examine if a combination of a cholesterol
      lowering-drug, simvastatin, with a sugar-lowering drug called rosiglitazone is more effective
      in improving vascular inflammation (irritation of the vessels that transport your blood) and
      other cardiovascular risk factors than the taking of simvastatin alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age 21-75 years Metabolic syndrome (must have 3 of the 5 components) elevated waist
      circumference &gt;40inches in men, &gt;35 inches in women elevated triglycerides &gt;150mg/dL reduced
      HDL &lt;40mg/dL in men&lt;50 in women elevated blood pressure &gt;130mmHg systolic, or &gt;85mmHg
      diastolic elevated fasting glucose &gt;100mg/dL
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in High-sensitivity C-reactive Protein</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in high-sensitivity C-reactive between baseline and 6 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Isoprostane</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in urinary isoprostane between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Malondialdehyde</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in Malondialdehyde between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Systolic Blood Pressure</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in office systolic blood pressure between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Office Diastolic Blood Pressure</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in office diastolic blood pressure between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (Ambulatory Blood Pressure Monitoring) Systolic Blood Pressure</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in (ambulatory blood pressure monitoring) systolic blood pressure between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (Ambulatory Blood Pressure Monitoring) Diastolic Blood Pressure</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in (ambulatory blood pressure monitoring) diastolic blood pressure between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low-density Lipoprotein</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in low-density lipoprotein between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in Triglycerides between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-density Lipoprotein</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in high-density lipoprotein between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Haemoglobin</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in glycosylated haemoglobin between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in fasting blood glucose between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in Insulin between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic Model Assessment for Insulin Resistance</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in homeostatic model assessment for insulin resistance between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adiponectin</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in Adiponectin between baseline and 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>change in body mass index between baseline and 6 month</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Simvastatin + Placebo Rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 40 mg Simvastatin + 1 tab Placebo Rosiglitazone daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin + rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 40 mg Simvastatin + 4 mg Rosiglitazone once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>4 mg daily</description>
    <arm_group_label>Simvastatin + rosiglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Rosiglitazone</intervention_name>
    <description>1 tab daily</description>
    <arm_group_label>Simvastatin + Placebo Rosiglitazone</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40 mg daily</description>
    <arm_group_label>Simvastatin + Placebo Rosiglitazone</arm_group_label>
    <arm_group_label>Simvastatin + rosiglitazone</arm_group_label>
    <other_name>Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-75 years

          -  Metabolic syndrome (3 of the 5 components)

          -  Elevated waist circumference &gt;40inches in men, &gt;35inches in women

          -  Elevated triglycerides &gt;150mg/dL

          -  Reduced HDL &lt;40mg/dL in men, &lt;50mg/dL in women

          -  Elevated blood pressure &gt;130mmHg systolic, &gt;85mmHg diastolic

          -  Elevated fasting glucose &gt;100mg/dL

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Stage 3 hypertension &gt;180mmHg systolic, &gt;110mmHg diastolic office blood pressure

          -  History of non-diabetic kidney disease

          -  Myocardial infarction of unstable angina within the past 6 months

          -  History of liver disease

          -  History of malignancy

          -  History of drug or alcohol abuse

          -  Treatment with corticosteroids

          -  Pregnancy or lactating women of women of child bearing potential who are not willing
             to use reliable contraception method during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Bakris, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>June 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2013</results_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>simvastatin 40 mg/day plus placebo</description>
        </group>
        <group group_id="P2">
          <title>Rosiglitazone</title>
          <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>9 lost to follow-up reasons uknown</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>simvastatin 40 mg/day plus placebo</description>
        </group>
        <group group_id="B2">
          <title>Rosiglitazone</title>
          <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="9.3"/>
                    <measurement group_id="B2" value="58.7" spread="12.1"/>
                    <measurement group_id="B3" value="57.03" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in High-sensitivity C-reactive Protein</title>
        <description>change in high-sensitivity C-reactive between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-sensitivity C-reactive Protein</title>
          <description>change in high-sensitivity C-reactive between baseline and 6 month</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="2.49"/>
                    <measurement group_id="O2" value="-0.61" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Isoprostane</title>
        <description>change in urinary isoprostane between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Isoprostane</title>
          <description>change in urinary isoprostane between baseline and 6 month</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="2.1"/>
                    <measurement group_id="O2" value="-1.09" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Malondialdehyde</title>
        <description>change in Malondialdehyde between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Malondialdehyde</title>
          <description>change in Malondialdehyde between baseline and 6 month</description>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="2.4"/>
                    <measurement group_id="O2" value="-1.52" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Office Systolic Blood Pressure</title>
        <description>change in office systolic blood pressure between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Office Systolic Blood Pressure</title>
          <description>change in office systolic blood pressure between baseline and 6 month</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.24" spread="12.5"/>
                    <measurement group_id="O2" value="-16.77" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Office Diastolic Blood Pressure</title>
        <description>change in office diastolic blood pressure between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Office Diastolic Blood Pressure</title>
          <description>change in office diastolic blood pressure between baseline and 6 month</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.59" spread="9.9"/>
                    <measurement group_id="O2" value="-9.46" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in (Ambulatory Blood Pressure Monitoring) Systolic Blood Pressure</title>
        <description>change in (ambulatory blood pressure monitoring) systolic blood pressure between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in (Ambulatory Blood Pressure Monitoring) Systolic Blood Pressure</title>
          <description>change in (ambulatory blood pressure monitoring) systolic blood pressure between baseline and 6 month</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="3.7"/>
                    <measurement group_id="O2" value="-1.08" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in (Ambulatory Blood Pressure Monitoring) Diastolic Blood Pressure</title>
        <description>change in (ambulatory blood pressure monitoring) diastolic blood pressure between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in (Ambulatory Blood Pressure Monitoring) Diastolic Blood Pressure</title>
          <description>change in (ambulatory blood pressure monitoring) diastolic blood pressure between baseline and 6 month</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.9"/>
                    <measurement group_id="O2" value="-0.69" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low-density Lipoprotein</title>
        <description>change in low-density lipoprotein between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low-density Lipoprotein</title>
          <description>change in low-density lipoprotein between baseline and 6 month</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.88" spread="41.2"/>
                    <measurement group_id="O2" value="-28.77" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>change in Triglycerides between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>change in Triglycerides between baseline and 6 month</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.32" spread="22.1"/>
                    <measurement group_id="O2" value="-42.47" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High-density Lipoprotein</title>
        <description>change in high-density lipoprotein between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-density Lipoprotein</title>
          <description>change in high-density lipoprotein between baseline and 6 month</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="7.9"/>
                    <measurement group_id="O2" value="2.77" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Haemoglobin</title>
        <description>change in glycosylated haemoglobin between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Haemoglobin</title>
          <description>change in glycosylated haemoglobin between baseline and 6 month</description>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.11"/>
                    <measurement group_id="O2" value="-0.22" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Blood Glucose</title>
        <description>change in fasting blood glucose between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Blood Glucose</title>
          <description>change in fasting blood glucose between baseline and 6 month</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" spread="10.9"/>
                    <measurement group_id="O2" value="-4.85" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin</title>
        <description>change in Insulin between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin</title>
          <description>change in Insulin between baseline and 6 month</description>
          <units>IU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="1.1"/>
                    <measurement group_id="O2" value="-3.47" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostatic Model Assessment for Insulin Resistance</title>
        <description>change in homeostatic model assessment for insulin resistance between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostatic Model Assessment for Insulin Resistance</title>
          <description>change in homeostatic model assessment for insulin resistance between baseline and 6 month</description>
          <units>HOMA units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="1.4"/>
                    <measurement group_id="O2" value="-2.08" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Adiponectin</title>
        <description>change in Adiponectin between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Adiponectin</title>
          <description>change in Adiponectin between baseline and 6 month</description>
          <units>Î¼g/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="1.3"/>
                    <measurement group_id="O2" value="4.15" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index</title>
        <description>change in body mass index between baseline and 6 month</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>simvastatin 40 mg/day plus placebo</description>
          </group>
          <group group_id="O2">
            <title>Rosiglitazone</title>
            <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index</title>
          <description>change in body mass index between baseline and 6 month</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="2.18"/>
                    <measurement group_id="O2" value="0.68" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>simvastatin 40 mg/day plus placebo</description>
        </group>
        <group group_id="E2">
          <title>Rosiglitazone</title>
          <description>simvastatin 40 mg/day plus rosiglitazone 4 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nonspecific muscle aches in lower extremities</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Joint aches</sub_title>
                <description>vague complaints of joint aches involving the knee, hip or ankle in all cases at least 2 or more of these joints</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. George Bakris</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-7936</phone>
      <email>bbrisky@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

